The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail vetinfo@hpra.ie


CEVAC TRANSMUNE lyophilisate for suspension for injection with solvent for chickens



Ceva Santé AnimaleVPA10815/005/001

Main Information

Trade NameCEVAC TRANSMUNE lyophilisate for suspension for injection with solvent for chickens
Active SubstancesLive, attenuated infectious bursal disease (IBD) virus, strain winterfield 2512, G-61
Dosage FormLyophilisate and solvent for suspension for injection
Licence HolderCeva Santé Animale
License Holder Address10, avenue de La Ballastière
33500 Libourne
France
Licence NumberVPA10815/005/001

Group Information

ATC CodeQI01AD09 avian infectious bursal disease virus (gumboro disease)
Therapeutic ClassImmunological
SpeciesChickens

Status

License statusAuthorised
Licence Issued26/11/2007
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation

Documents

Summary of Product Characteristics *PDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
VariationsPDF Version

* The PDF document, together with the national-specific product information on this page, constitute the authorised SPC
« Back